Lisa M Bebell1,2,3, Kalynn Parks4, Mylinh H Le3, Joseph Ngonzi5, Julian Adong5, Adeline A Boatin2,6, Ingrid V Bassett1,3, Mark J Siedner1,2,3, Alison D Gernand4, Drucilla J Roberts7. 1. Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA. 2. MassGeneral Global Health, Massachusetts General Hospital, Boston, Massachusetts, USA. 3. Medical Practice Evaluation Center of Massachusetts General Hospital, Boston, Massachusetts, USA. 4. Department of Nutritional Sciences, Pennsylvania State University, University Park, Pennsylvania, USA. 5. Mbarara University of Science and Technology, Mbarara, Uganda. 6. Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, Massachusetts, USA. 7. Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Women with human immunodeficiency virus (HIV) (WHIV) are at higher risk of adverse birth outcomes. Proposed mechanisms for the increased risk include placental arteriopathy (vasculopathy) and maternal vascular malperfusion (MVM) due to antiretroviral therapy and medical comorbid conditions. However, these features and their underlying pathophysiologic mechanisms have not been well characterized in WHIV. METHODS: We performed gross and histologic examination and immunohistochemistry staining for vascular endothelial growth factor A (VEGF-A), a key angiogenic factor, on placentas from women with ≥1 MVM risk factors including: weight below the fifth percentile, histologic infarct or distal villous hypoplasia, nevirapine-based antiretroviral therapy, hypertension, and preeclampsia/eclampsia during pregnancy. We compared pathologic characteristics by maternal HIV serostatus. RESULTS: Twenty-seven of 41 (placentas 66%) assessed for VEGF-A were from WHIV. Mean maternal age was 27 years. Among WHIV, median CD4 T-cell count was 440/µL, and the HIV viral load was undetectable in 74%. Of VEGF-A-stained placentas, both decidua and villous endothelium tissue layers were present in 36 (88%). VEGF-A was detected in 31 of 36 (86%) with decidua present, and 39 of 40 (98%) with villous endothelium present. There were no differences in VEGF-A presence in any tissue type by maternal HIV serostatus (P = .28 to >.99). MVM was more common in placentas selected for VEGF-A staining (51 vs 8%; P < .001). CONCLUSIONS: VEGF-A immunostaining was highly prevalent, and staining patterns did not differ by maternal HIV serostatus among those with MVM risk factors, indicating that the role of VEGF-A in placental vasculopathy may not differ by maternal HIV serostatus.
BACKGROUND: Women with human immunodeficiency virus (HIV) (WHIV) are at higher risk of adverse birth outcomes. Proposed mechanisms for the increased risk include placental arteriopathy (vasculopathy) and maternal vascular malperfusion (MVM) due to antiretroviral therapy and medical comorbid conditions. However, these features and their underlying pathophysiologic mechanisms have not been well characterized in WHIV. METHODS: We performed gross and histologic examination and immunohistochemistry staining for vascular endothelial growth factor A (VEGF-A), a key angiogenic factor, on placentas from women with ≥1 MVM risk factors including: weight below the fifth percentile, histologic infarct or distal villous hypoplasia, nevirapine-based antiretroviral therapy, hypertension, and preeclampsia/eclampsia during pregnancy. We compared pathologic characteristics by maternal HIV serostatus. RESULTS: Twenty-seven of 41 (placentas 66%) assessed for VEGF-A were from WHIV. Mean maternal age was 27 years. Among WHIV, median CD4 T-cell count was 440/µL, and the HIV viral load was undetectable in 74%. Of VEGF-A-stained placentas, both decidua and villous endothelium tissue layers were present in 36 (88%). VEGF-A was detected in 31 of 36 (86%) with decidua present, and 39 of 40 (98%) with villous endothelium present. There were no differences in VEGF-A presence in any tissue type by maternal HIV serostatus (P = .28 to >.99). MVM was more common in placentas selected for VEGF-A staining (51 vs 8%; P < .001). CONCLUSIONS: VEGF-A immunostaining was highly prevalent, and staining patterns did not differ by maternal HIV serostatus among those with MVM risk factors, indicating that the role of VEGF-A in placental vasculopathy may not differ by maternal HIV serostatus.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: Emily Wright; Melanie C Audette; Xiang Y Ye; Sarah Keating; Barry Hoffman; Stephen J Lye; Prakesh S Shah; John C Kingdom Journal: Obstet Gynecol Date: 2017-11 Impact factor: 7.661
Authors: Andrea L Conroy; Chloe R McDonald; Joel L Gamble; Peter Olwoch; Paul Natureeba; Deborah Cohan; Moses R Kamya; Diane V Havlir; Grant Dorsey; Kevin C Kain Journal: Am J Obstet Gynecol Date: 2017-10-12 Impact factor: 8.661
Authors: Moses M Obimbo; Yan Zhou; Michael T McMaster; Craig R Cohen; Zahida Qureshi; John Ong'ech; Julius A Ogeng'o; Susan J Fisher Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Sepideh Dolatshahi; Audrey L Butler; Mark J Siedner; Joseph Ngonzi; Andrea G Edlow; Julian Adong; Madeleine F Jennewein; Caroline Atyeo; Ingrid V Bassett; Drucilla J Roberts; Douglas A Lauffenburger; Galit Alter; Lisa M Bebell Journal: Clin Infect Dis Date: 2022-10-12 Impact factor: 20.999
Authors: Lisa M Bebell; Joseph Ngonzi; Frederick A Meier; Chrystalle Katte Carreon; Abraham Birungi; Vanessa B Kerry; Raymond Atwine; Drucilla J Roberts Journal: Front Med (Lausanne) Date: 2022-07-08